X0306 4 2014-02-05 1 0001346830 Cara Therapeutics, Inc. CARA 0001257444 ALTA BIOPHARMA PARTNERS III LP ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001280234 ALTA BIOPHARMA MANAGEMENT III LLC C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001280265 ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001280238 ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001198321 CHAMPSI FARAH C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 0001211840 HURWITZ EDWARD C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 1 0 1 0 0001198332 PENHOET EDWARD C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO CA 94111 0 0 1 0 Common Stock 2014-02-05 4 C 0 1118675 0.00 A 1118675 I See Footnote Common Stock 2014-02-05 4 C 0 531442 0.00 A 1650117 I See Footnote Common Stock 2014-02-05 4 P 0 103330 11.00 A 1753447 I See Footnote Common Stock 2014-02-05 4 C 0 75129 0.00 A 75129 I See Footnote Common Stock 2014-02-05 4 C 0 35691 0.00 A 110820 I See Footnote Common Stock 2014-02-05 4 P 0 6940 11.00 A 117760 I See Footnote Common Stock 2014-02-05 4 C 0 27568 0.00 A 27568 I See Footnote Common Stock 2014-02-05 4 C 0 13097 0.00 A 40665 I See Footnote Common Stock 2014-02-05 4 P 0 2547 11.00 A 43212 I See Footnote Series C Preferred Stock 2014-02-05 4 C 0 2363654 0.00 D Common Stock 1118675 0 I See Footnote Series C Preferred Stock 2014-02-05 4 C 0 158741 0.00 D Common Stock 75129 0 I See Footnote Series C Preferred Stock 2014-02-05 4 C 0 58250 0.00 D Common Stock 27568 0 I See Footnote Series D Preferred Stock 2014-02-05 4 C 0 1328604 0.00 D Common Stock 531442 0 I See Footnote Series D Preferred Stock 2014-02-05 4 C 0 89227 0.00 D Common Stock 35691 0 I See Footnote Series D Preferred Stock 2014-02-05 4 C 0 32742 0.00 D Common Stock 13097 0 I See Footnote The Series C Preferred Stock held by the reporting persons automatically converted on a 1-for-2.1129 basis into shares of common stock upon the closing of the issuer's initial public offering. These shares are held of record by Alta BioPharma Partners III, L.P. ("ABP III"). Alta BioPharma Management III, LLC ("ABM III") is the general partner of ABP III. Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are directors of ABM III and may be deemed to share dispositive and voting power over the shares held by ABP III. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein. The Series D Preferred Stock held by the reporting persons automatically converted on a 1-for-2.5 basis into shares of common stock upon the closing of the issuer's initial public offering. These shares are held of record by Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("GmbH"). ABM III is the managing limited partner of GmbH. Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are directors of ABM III and may be deemed to share dispositive and voting power over the shares held by GmbH. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein. These shares are held of record by Alta Embarcadero BioPharma Partners III, LLC ("Embarcadero"). Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are the managers of Embarcadero and may be deemed to share dispositive and voting power over the shares held by Embarcadero. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein. Please note that all of these reporting persons are no longer subject to Section 16 Form 4 or Form 5 obligations, with the exception of Edward Hurwitz, who will have an ongoing Section 16 reporting obligation as a director of the issuer. /s/Darren DeStefano, Attorney-in-Fact 2014-02-05 Darren DeStefano, Attorney-in-Fact 2014-02-05 Darren DeStefano, Attorney-in-Fact 2014-02-05 Darren DeStefano, Attorney-in-Fact 2014-02-05 Darren DeStefano, Attorney-in-Fact 2014-02-05 Darren DeStefano, Attorney-in-Fact 2014-02-05 Darren DeStefano, Attorney-in-Fact 2014-02-05